Enzalutamide in metastatic prostate cancer before chemotherapy

New England Journal of Medicine

Volumn 371, Issue 5, 2014, Pages 424-433

  Beer, Tomasz M ^a   Armstrong, A J ^b   Rathkopf, D E ^c   Loriot, Y ^d   Sternberg, C N ^e   Higano, C S ^f   Iversen, P ^g   Bhattacharya, S ^h   Carles, J ⁱ   Chowdhury, S ^j   Davis, I D ^l   De Bono, J S ^k   Evans, C P ⁿ   Fizazi, K ^d   Joshua, A M ^o   Kim, C S ^r   Kimura, G ^s   Mainwaring, P ^m   Mansbach, H ^h   Miller, K ^t   Noonberg, S B ^h   Perabo, F ^u   Phung, D ^u   Saad, F ^p   Scher, H I ^c   Taplin, M E ^v   Venner, P M ^q   Tombal, B ^w   more..

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h Medivation Inc   (United States)

ⁱ VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^j GUY S HOSPITAL   (United Kingdom)

^k ROYAL MARSDEN HOSPITAL   (United Kingdom)

^l MONASH UNIVERSITY   (Australia)

^m ICON Cancer Care   (Australia)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o PRINCESS MARGARET HOSPITAL   (Canada)

^p CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^q UNIVERSITY OF ALBERTA   (Canada)

^r Asan Medical Center   (South Korea)

^s NIPPON MEDICAL SCHOOL   (Japan)

^t CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^u ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^v DANA FARBER CANCER INSTITUTE   (United States)

^w CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; DOCETAXEL; ENZALUTAMIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ACUTE CORONARY SYNDROME; ACUTE KIDNEY FAILURE; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CANCER MORTALITY; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; HEART ATRIUM FIBRILLATION; HOT FLUSH; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RISK REDUCTION; SURVIVAL RATE; TREATMENT DURATION;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ANDROGEN RECEPTOR ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; HUMANS; MALE; NEOPLASM METASTASIS; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SURVIVAL ANALYSIS;

EID: 84904871070     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1405095     Document Type: Article

References (25)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90. [Erratum, CA Cancer J Clin 2011;61:134.]
2. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
3. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300. (Pubitemid 27318990)
4. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472-9. (Pubitemid 43779173)
5. Nair B, Wilt T, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 2002;1:CD003506.
6. Studer UE, Whelan P, Wimpissinger F, et al. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up. Eur Urol 2013 July 24 (Epub ahead of print).
7. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97.
8. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48. [Erratum, N Engl J Med 2013;368:584.]
9. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
10. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9. (Pubitemid 38524696)
11. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009;15:4792-8.
12. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-54.
13. Attard G, de Bono JS. Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clin Cancer Res 2011;17:3867-75.
14. Massard C, Fizazi K. Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res 2011;17:3876-83.
15. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90.
16. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437-46.
17. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59.
18. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65-70.
19. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
20. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12. (Pubitemid 39315317)
21. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54.
22. Harris V, Lloyd K, Forsey S, Rogers P, Roche M, Parker C. A population-based study of prostate cancer chemotherapy. Clin Oncol (R Coll Radiol) 2011;23:706-8.
23. Engel-Nitz NM, Alemayehu B, Parry D, Nathan F. Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population. Cancer Manag Res 2011;3:233-45.
24. Lissbrant IF, Garmo H, Widmark A, Stattin P. Population-based study on use of chemotherapy in men with castration resistant prostate cancer. Acta Oncol 2013;52:1593-601.
25. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23.